The Jorge Talks Peps research library
A guide to what peptide and related compound research actually says. Compare human studies, early findings, formulation differences and the limits behind popular dosage claims.
Find a compound ↓Best for and vs guides ↗Supplies and accessories ↗
Browse the library
30 guides
Metabolic and cellular research
5-Amino-1MQ is a small organic molecule (an NNMT inhibitor), not a peptide, and its mechanism differs fundamentally from the amino-acid chain compounds it is often marketed next to. Reviews describe NNMT biology broadly across cardiovascular, metabolic, and oncology contexts; specific rodent obesity studies using 5-Amino-1MQ as the tool compound are cited in NNMT review literature.
Read the research →Neurologic research
Adamax is sold as a distinct marketed peptide product name, described as related to Semax, but the sources reviewed contained no study identifying Adamax by that name, its exact sequence relationship to Semax, or independent research on it. Readers should not assume Adamax shares Semax's studied effects without a structural and study-level confirmation not available in this review.
Read the research →Repair and tissue research
AHK-Cu is a distinct tripeptide-copper complex, structurally related to but not identical to GHK-Cu. It is not an FDA approved drug. The primary study identified used ex vivo human hair follicle organ culture and in vitro dermal papilla cell culture, not living human subjects or an animal model.
Read the research →Metabolic and cellular research
AOD-9604 refers to a specific 16-amino-acid fragment of the human growth hormone sequence, chemically distinct from full-length growth hormone itself. Reign Peptide's product is a lyophilized research-chemical powder of this fragment sold for laboratory use, not an approved drug and not equivalent to full-length growth hormone.
Read the research →Neurologic research
ARA-290/cibinetide is an investigational peptide studied in registered clinical trials; it has not been confirmed in the sources reviewed as an FDA approved drug for any indication. It is engineered to be distinct from erythropoietin itself, avoiding erythropoietin's blood-forming effects, according to the trial literature.
Read the research →Repair and tissue research
BPC-157 is not FDA approved as a drug and is not the same as any prescription medicine. It is sold by suppliers as a research chemical, and formulations, purity and dosing vary by manufacturer and are not standardized across products.
Read the research →Growth hormone research
CJC-1295 No DAC (Modified GRF 1-29) is chemically distinct from CJC-1295 with DAC in that it lacks the affinity-complex modification, which is reported elsewhere in the pharmacology literature to be the feature responsible for extending duration of action; without it, the peptide is expected to behave more like a short-acting GHRH fragment. Reign Peptide's product is a research-chemical vial of this shorter sequence, not the DAC-conjugated molecule and not a pharmaceutical product.
Read the research →Research blends
This is a supplier-formulated combination product, not a molecule studied in the literature. CJC-1295 No DAC and ipamorelin are each distinct peptides with their own pharmacology; combining them in one vial is a manufacturing and convenience decision by the supplier, not a tested pharmacological entity, and no ratio-specific research exists for this or any other blend ratio in the sources reviewed.
Read the research →Growth hormone research
CJC-1295 with DAC refers to the specific GHRH-analog-plus-affinity-complex molecule studied in the cited pharmacology trial, developed by a pharmaceutical sponsor for that research program. Reign Peptide's product is a separately manufactured research-chemical vial of the same class labeled for laboratory use, with no confirmed identity match, purity certification tie, or sponsor relationship to the studied compound.
Read the research →Neurologic research
DSIP is a synthetic version of a naturally described nonapeptide; the studies reviewed used synthetic DSIP administered intravenously in a clinical research setting, not the nasal spray or other consumer routes sold today, so route-specific effects are not established as equivalent.
Read the research →Growth hormone research
Epithalon is a small synthetic tetrapeptide distinct from Epithalamin, the original bovine pineal extract it was designed to model; studies of the extract and of the synthetic peptide are not automatically interchangeable. A research-grade vial sold today is the synthetic tetrapeptide, not a pineal gland extract product.
Read the research →Repair and tissue research
GHK-Cu is best supported as a topical cosmetic ingredient studied in dermatology research; it is not an FDA approved drug for injectable use. Cosmetic-grade topical products and supplier research-chemical vials are different formulations and are not interchangeable based on the sources reviewed.
Read the research →Metabolic and cellular research
Glutathione is a naturally occurring tripeptide (glutamate-cysteine-glycine) present in the body; supplement and research-chemical products vary widely in formulation, route and bioavailability, and these differences have been shown to matter clinically according to the pharmacokinetic literature reviewed.
Read the research →Growth hormone research
Ipamorelin refers to a specific five-amino-acid peptide sequence. Reign Peptide's product is a lyophilized research-chemical powder of this sequence labeled for laboratory use; it is not manufactured or regulated as a pharmaceutical product and has no approved clinical formulation for comparison.
Read the research →Research blends
KLOW is a commercial blend name, not a peptide with its own identity in the research literature. Per the supplier product description reviewed, the listed components are GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg and KPV 10mg per 80mg vial; this composition is supplier-stated, not verified against an independent laboratory or a published study of the blend.
Read the research →Immune research
KPV is a small peptide fragment studied in laboratory and animal research settings; it is not an FDA approved drug. It should not be confused with full-length alpha-MSH analogs such as afamelanotide, which have separate approval and safety data.
Read the research →Pigmentation and sexual health
Afamelanotide, the approved drug, is manufactured and delivered as a 16mg subcutaneous implant placed by a clinician for a specific rare disease indication. Reign Peptide's Melanotan 1 is a lyophilized research-chemical powder of the same or closely related linear peptide sequence, intended by the seller for laboratory reconstitution, not the approved implant device, route, or indication; the two are not interchangeable products.
Read the research →Metabolic and cellular research
MOTS-c is a naturally occurring 16-amino-acid mitochondrial-derived peptide, distinct from a synthesized research reagent sold under the same name. Studies use it in mouse and cell models or measure endogenous serum levels in patients; a manufactured vial is a research chemical, not the same regulatory entity as the endogenous signaling peptide characterized in these papers.
Read the research →Metabolic and cellular research
NAD+ is a small-molecule coenzyme, chemically unrelated to peptides, present naturally in all cells. Human studies vary widely by what was actually administered (NAD+ itself, nicotinamide riboside, or nicotinamide mononucleotide), by what tissue compartment was measured (whole blood versus plasma), and by route (oral, sublingual, intravenous), so results are not interchangeable between formulations.
Read the research →Neurologic research
Pinealon is described in the bioregulator peptide literature as a short synthetic peptide intended to model regulatory activity attributed to pineal-associated short peptides in that research tradition; it is a distinct compound from other pineal-associated products such as Epithalon, and findings for one should not be assumed to transfer to the other.
Read the research →Pigmentation and sexual health
Bremelanotide as approved (Vyleesi) is dispensed as a single-use, prefilled autoinjector for a specific FDA-cleared indication in a defined patient population. Reign Peptide sells the same peptide sequence as a lyophilized powder vial or nasal spray for research use, not as the approved autoinjector device, and no bioequivalence between these research formats and Vyleesi was identified in the sources reviewed.
Read the research →Metabolic and cellular research
Retatrutide as studied by Eli Lilly is a proprietary, pharmaceutical-grade investigational compound dosed under monitored clinical trial protocols. Vials sold by peptide suppliers as research chemicals are separately synthesized by unrelated manufacturers; no publicly available data links their purity, formulation, or biological activity to the trial drug substance.
Read the research →Neurologic research
Selank is a synthetic peptide analogue of tuftsin, an endogenous immunomodulatory tetrapeptide, extended with additional amino acids; it is not the same molecule as tuftsin itself, and findings for one should not be assumed to apply directly to the other.
Read the research →Neurologic research
Semax is a synthetic peptide built on the ACTH(4-10) sequence with added amino acids (sometimes described as ACTH(4-7)PGP), distinct from natural ACTH itself and from related synthetic analogues such as ACTH(6-9)PGP studied in the same research programs.
Read the research →Metabolic and cellular research
Elamipretide is the approved drug name for the specific pharmaceutical formulation of SS-31 developed by Stealth BioTherapeutics and reviewed by FDA for a narrow, ultra-rare disease indication under a specific dose, route, and manufacturing process. A research-labeled SS-31 vial sold outside that regulatory pathway is not verified to be the same formulation, purity, or clinical entity as the approved drug, even if the peptide sequence is intended to be identical.
Read the research →Repair and tissue research
TB-500 as sold commercially is a synthetic peptide marketed as related to thymosin beta-4, not an FDA approved drug. The sources reviewed studied thymosin beta-4 or specific engineered variants such as PEGylated thymosin beta-4, which may differ in structure, purity and pharmacokinetics from a given supplier's TB-500 product.
Read the research →Growth hormone research
Tesamorelin the approved drug is a specific peptide sequence manufactured and dosed as Egrifta by its FDA-approved sponsor for a narrow HIV lipodystrophy indication. Reign Peptide's tesamorelin vials are labeled as a research chemical of the same peptide sequence sold for laboratory use, not the approved drug product, with no confirmed manufacturing or bioequivalence link to Egrifta.
Read the research →Research blends
Tesamorelin as approved (Egrifta) and tesamorelin as sold in this research blend are not the same regulatory product; the approved drug is manufactured and dosed as a single-agent injection for a defined patient population, while this blend combines the same peptide sequence, research-grade, with ipamorelin in one vial for laboratory use, a combination not evaluated in the cited trials.
Read the research →Immune research
Thymosin alpha-1 is a defined 28 amino acid peptide with a substantial history of clinical trial research, distinct from research-chemical peptides that have only preclinical data. This page does not address regulatory approval status in any jurisdiction, since that was not verified from an official regulatory source in this research.
Read the research →Research blends
This is a commercial blend product name. The closest evidence identified is a controlled rat experiment that included a combined BPC-157 plus TB-500 treatment arm, using research doses selected by the study investigators, not the specific per-vial ratio a supplier sells as Wolverine Blend.
Read the research →No guides match these filters. Try a shorter name or reset the filters.
Read the label before the claim
Evidence depends on population and formulation.
Laboratory or animal findings, not clinical validation.
Direct evidence does not establish a personal use protocol.
Component studies do not validate this commercial blend.
Human studies do not automatically validate every formulation or use. A blend cannot borrow the clinical status of its ingredients. NAD+ and 5-Amino-1MQ are related research compounds, not peptides.
Reign Peptide · Business disclosure
Jorge Abreu is involved in Reign Peptide. Links to Reign are a business connection, not an independent endorsement. Reign lists these products for laboratory research, not human consumption.
Use the listing to check the labeled identity, amount and available batch documentation. A purity result alone does not verify sterility, clinical suitability or equivalence to a medicine used in a trial.
Names and sizes are product labels, not dosing recommendations. Confirm current details with the seller.
More from Jorge Talks Peps
Check concentration and volume calculations. Arithmetic does not establish a safe dose.
Open the calculator →